Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc. focuses on the generation of antibody therapeutics, as well as on the use of somatic hypermutation (SHM) for antibody discovery and optimization. The company’s SHM-XEL platform couples human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies that replicates key features of the human immune system. It develops ANB020Its, an anti-IL-33 lead candidate antibody that inhibits IL-33 cytokine function by blocking interaction with receptor at low picomolar potency; a portfolio of antibodies for immuno-oncology to modulate the function of T cell negative regulators, including PD-1, TIM-3, and LAG-3; ANB012, an anti-ActRIIb a...
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Senior Director of Target Biology
Compensation as of Fiscal Year 2014.
AnaptysBio, Inc. Key Developments
AnaptysBio, Inc. Presents at BIO International Convention, Jun-25-2014 10:45 AM
Jun 17 14
AnaptysBio, Inc. Presents at BIO International Convention, Jun-25-2014 10:45 AM. Venue: San Diego Convention Center, San Diego, California, United States.
AnaptysBio, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 08:30 AM
Mar 19 14
AnaptysBio, Inc. Presents at UBS Global Healthcare Conference, May-19-2014 08:30 AM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director.
AnaptysBio, Inc. and Tesaro, Inc. Announce Strategic Immuno-Oncology Antibody Collaboration
Mar 13 14
AnaptysBio, Inc. announced a strategic immuno-oncology collaboration with TESARO, Inc. Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody candidates from these programs are expected to enter clinical trials over the next 18 to 24 months. Under the terms of this agreement, TESARO will pay an upfront license fee of $17 million, as well as provide funding of costs incurred by AnaptysBio related to the development programs. For each development program, AnaptysBio is eligible to receive milestone payments of $18 million if certain research and development events are achieved and an additional $90 million associated with certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration and certain commercial milestone payments if specified levels of annual worldwide net sales are attained. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities. Each of the antibodies licensed under this collaboration has been developed using AnaptysBio's proprietary SHM-XEL platform. By replicating the natural process of somatic hypermutation in vitro, the platform permits rapid generation of high potency therapeutic antibodies selected for desired functional activity and robust biophysical properties. The SHM-XEL platform has been successful in generating therapeutic antibodies for AnaptysBio's internal pipeline and under various pharmaceutical company partnerships.
Similar Private Companies By Industry
Recent Private Companies Transactions